7 research outputs found

    Pharmacological protection of mitochondrial function mitigates acute limb ischemia/reperfusion injury

    No full text
    © 2016 We describe several novel curcumin analogues that possess both anti-inflammatory antioxidant properties and thrombolytic activities. The therapeutic efficacy of these curcumin analogues was verified in a mouse ear edema model, a rat arterial thrombosis assay, a free radical scavenging assay performed in PC12 cells, and in both in vitro and in vivo ischemia/reperfusion models. Our findings suggest that their protective effects partially reside in maintenance of optimal mitochondrial function

    Cardioprotection effects of LPTC-5 involve mitochondrial protection and dynamics

    No full text
    We recently designed and synthesized a series of novel levodopa–peptide–TEMPO conjugates (LPTCs). Among these compounds, LPTC-5 possesses both free-radical scavenging potential and mitochondrial fusion-promoting activity. The free-radical scavenging capacity of LPTC-5 was confirmed using a PC12 cell survival assay. LPTC-5 could restore the mitochondrial tubular network following genetically induced fragmentation. The therapeutic efficacy of LPTC-5 was then examined employing in vitro and in vivo ischemia/reperfusion (I/R) models. LPTC-5 protected cells from mitochondrial reactive oxygen species overproduction and inhibited cytochrome c release in a simulated I/R cellular model. Additionally, LPTC-5 attenuated organ damage in a cardiac I/R animal model. The data suggest that LPTC-5 exerts cardioprotection via modulation of mitochondrial fission/fusion dynamics, ultimately improving mitochondrial function and cardiac function

    Indole-TEMPO conjugates alleviate ischemia-reperfusion injury via attenuation of oxidative stress and preservation of mitochondrial function

    No full text
    © 2017 Mitochondrial oxidative damage contributes to a wide range of pathologies including ischemia/reperfusion injury. Accordingly, protecting mitochondria from oxidative damage should possess therapeutic relevance. In the present study, we have designed and synthesized a series of novel indole-TEMPO conjugates that manifested good anti-inflammatory properties in a murine model of xylene-induced ear edema. We have demonstrated that these compounds can protect cells from simulated ischemia/reperfusion (s-I/R)-induced reactive oxygen species (ROS) overproduction and mitochondrial dysfunction. Furthermore, we have demonstrated that indole-TEMPO conjugates can attenuate organ damage induced in rodents via intestinal I/R injury. We therefore propose that the pharmacological profile and mechanism of action of these indole-TEMPO conjugates involve convergent roles, including the ability to decrease free radical production via lipid peroxidation which couples to an associated decrease in ROS-mediated activation of the inflammatory process. We further hypothesize that the protective effects of indole-TEMPO conjugates partially reside in maintaining optimal mitochondrial function

    Anti-inflammatory, analgesic and antioxidant activities of novel kyotorphin-nitroxide hybrid molecules

    No full text
    Mitochondrial oxidative damage contributes to a wide range of pathologies, including ischemia/reperfusion (I/R) injury, cardiovascular disorders and neurodegenerative diseases. Accordingly, protecting mitochondria from oxidative damage should possess therapeutic relevance. In the present study, we have designed and synthesized a series of novel kyotorphin-nitroxide hybrid molecules, and examined their free radical scavenging activities, in addition to their anti-inflammatory and analgesic activities. We have further characterized these compounds in a simulated I/R cellular model. Our findings suggest that the protective effects of kyotorphin-nitroxides partially reside in maintaining optimal mitochondrial function

    Systematic review and meta-analyses of lead (Pb) concentrations in environmental media (soil, dust, water, food, and air) reported in the United States from 1996 to 2016

    No full text

    Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

    No full text
    corecore